TOPIC

/ company

Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals: A leading Chinese pharmaceutical company, headquartered in Lianyungang, Jiangsu, with corporate offices in Shanghai and a global presence including R&D centres in the US and Europe. It specialises in the research, development, manufacturing, and distribution of innovative drugs, primarily focusing on oncology, surgical medicines, cardiovascular, and metabolic diseases. The company is recognised as China’s largest listed pharmaceutical firm and consistently ranks among the top global pharmaceutical companies. Its overall business focus is on innovation, significant R&D investment, and global expansion to address unmet medical needs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

20 Dec 2025 - 8:57AM

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

19 Dec 2025 - 8:30AM

China stock market

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

4 Dec 2025 - 3:01PM

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

4 Dec 2025 - 10:51AMvideocam

A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

11 Dec 2025 - 10:09AM

United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

7 Oct 2025 - 2:18PM

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

4 Oct 2025 - 10:56AM

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

26 Sep 2025 - 12:15PM

Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

25 Sep 2025 - 5:43PM

Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

23 Sep 2025 - 7:30AM

Employees work on the production line of Shijiazhuang No 4 Pharmaceutical in Shijiazhuang, Hebei province. Photo: VCG/VCG via Getty Images

Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

22 Sep 2025 - 5:21PM

China’s weight-loss drugs market could grow to US$5.6 billion in 2035, according to Goldman Sachs. Photo: Shutterstock

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

19 Sep 2025 - 4:50PM

IPO

Zijin Gold’s Hong Kong IPO draws GIC, Millennium and Hillhouse, sources say

The company could raise more than US$3 billion and could start taking orders from other investors and the public as soon as Friday.

18 Sep 2025 - 6:25PM

Banking & finance

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

10 Sep 2025 - 2:25PM

Investor focus was on companies that address cardiovascular, cancer and other life-threatening conditions. Photo: Shutterstock

IPO

Hong Kong IPO pipeline swells as Chinese tech listings lure global investors

More than 200 companies await approval amid ‘strong global interest in China’s tech sector’, CEO of bourse operator says.

5 Sep 2025 - 3:30PM

Hong Kong Exchanges and Clearing CEO Bonnie Chan Yiting speaks the the bourse operator’s Future Tech Summit on September 5, 2025 in Hong Kong. Photo: Handout

Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

5 Sep 2025 - 4:20PM

China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

2 Sep 2025 - 2:58PMvideocam

Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

18 Aug 2025 - 7:30AM

Workers inside Hansoh Pharmaceutical. Photo: Handout

Biomedicine: Companies

Opinion | Biotech successes helping Chinese intellectual property go global

After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own innovations.

5 Aug 2025 - 5:30AMvideocam

Wealth management

Shareholders of Chinese firms eye Hong Kong for family offices: asset manager

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family offices.

21 Jul 2025 - 11:38AM

Wang Fengyu, founder and chairman of Hong Kong-based Oakwise Capital. Photo: Handout

Help preserve 120 years of quality journalism.

SUPPORT NOW

Jiangsu Hengrui Pharmaceuticals

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s pharmaceutical industry transforms into a global innovation powerhouse

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

.css-1m2rp1p{color:#34b8b5;}Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Zijin Gold’s Hong Kong IPO draws GIC, Millennium and Hillhouse, sources say

The company could raise more than US$3 billion and could start taking orders from other investors and the public as soon as Friday.

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

Hong Kong IPO pipeline swells as Chinese tech listings lure global investors

More than 200 companies await approval amid ‘strong global interest in China’s tech sector’, CEO of bourse operator says.

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

.css-sioo19{color:#c79a00;}Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Opinion | Biotech successes helping Chinese intellectual property go global

After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own innovations.

Shareholders of Chinese firms eye Hong Kong for family offices: asset manager

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family offices.

Opinion | How China engineered the rapid rise of its drug innovation industry

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge